This article is more than 5 years old. Information may no longer be current.

RM-131 safely, effectively treated symptoms in patients with diabetic gastroparesis

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

CHICAGO — Patients with diabetic gastroparesis displayed increased gastric emptying and improvement in vomiting after treatment with the selective ghrelin pentapeptide relamorelin-131, according to new research presented at a late-breaking session at Digestive Disease Week.

In a phase 2 trial, researchers randomly assigned 204 patients with diabetic gastroparesis (DG) (mean age, 55.1 years; 32.3% men) into a double blind, placebo-controlled study for 28 days. Patients were enlisted to take two daily injections of relamorelin-131 10 mcg (RM-131; Rhythm) before an evening meal (n=67), RM-131 10 mcg before breakfast and an evening meal (n=68) or placebo (n=69). Patients’ daily symptoms were recorded on a 0-10 scale, and a gastric emptying breath test (GEBT) was performed at baseline and on day 28.

Patients who received RM-131 before breakfast and evening meals showed accelerated GE (P<.03), the study’s primary endpoint, and an improvement in vomiting (P=.033), compared with placebo patients. Results for patients who took RM-131 only before evening meals were not presented.

Post-hoc analysis of 119 patients with baseline vomiting revealed that RM-131 had a positive effect on GE, and overall weekly vomiting was reduced by 63%. This subgroup also exhibited improvements in nausea, bloating, early satiety and abdominal pain, compared with the placebo arm (P<.043). Few adverse events occurred, according to the study.

“In summary, RM-131 10 mcg twice daily showed more efficacy than once daily,” Anthony Lembo, MD, gastroenterologist at Beth Israel Deaconess Medical Center, Boston, said at the conference. “In post-hoc analysis in the subgroup of patients, RM-131 10 mcg twice daily is effective in all endpoints. There were no safety concerns seen in the studies.” - by Melinda Stevens

For more information:

Lembo A. #929a. Presented at: Digestive Disease Week 2014; May 3-6; Chicago.

Disclosure: The researchers report numerous financial disclosures.